Pfizer, IncNYSE: PFE
Health Care · Pharmaceuticals
$26.37
-1.25%
Vol: 45.2M
Research Digest
Friday, May 1, 2026
Pfizer to report Q1 2026 earnings May 5 amid patent settlement on Vyndamax extending through 2031
Pfizer will report Q1 2026 earnings before market open May 5 with an 10 a.m. EDT analyst call. Analysts expect $0.77 EPS on $13.89 billion revenue. The company secured patent settlement extending Vyndamax (transthyretin amyloidosis drug) through 2031, stabilizing revenue. Pfizer's Elrexfio met primary efficacy goals in late-stage blood cancer trials. The firm declared a $0.43 second-quarter dividend (350th consecutive). Goldman Sachs cut PFE's price target to $26, citing revenue headwinds. Analysts average Buy rating with $29.29 target.
Previous Market Intelligence
13 daysApr 30Pfizer Extends VYNDAMAX Patent to 2031 via Settlement with Generic Makers; Q1 Earnings May 5Positive▶
Pfizer announced April 28 settlement with generic manufacturers Dexcel, Hikma, and Cipla extending VYNDAMAX (cardiomyopathy treatment) patent exclusivity to June 1, 2031 (vs prior 2029 expiry). Positive Phase 3 results reported for ELREXFIO (multiple myeloma) as monotherapy. Stock down 1.16% to $26.48 ahead of May 5 earnings (expected $0.74 EPS). Company targets 2026 revenue $59.5-62.5B and adjusted EPS $2.80-3.00. Q2 dividend declared at $0.43/share (350th consecutive quarter). Analyst consensus "Buy" with PT $29.29 (+11.5% upside).
Apr 29Pfizer's ELREXFIO meets Phase 3 myeloma endpoint; VYNDAMAX patent extended to 2031Positive▶
Pfizer announced positive Phase 3 MagnetisMM-5 results for ELREXFIO (elranatamab) in relapsed/refractory multiple myeloma on April 28, demonstrating statistically significant improvement in progression-free survival vs standard-of-care. Company also reached three settlement agreements extending VYNDAMAX patent expiry to June 1, 2031 with stable revenues projected 2028-2031. Board declared $0.43 Q2 2026 dividend (350th consecutive quarterly). Q1 earnings report May 5. Analyst consensus: 14 analysts rate Buy with $29.29 target (11.5% upside).
Apr 16Pfizer and Valneva announce Lyme disease vaccine demonstrates 70%+ efficacy in Phase 3 VALOR trial; Q1 earnings due May 5Positive▶
Pfizer and Valneva announced that their investigational 6-valent OspA-based Lyme disease vaccine demonstrated over 70% efficacy in preventing Lyme disease in individuals aged five years and above in the Phase 3 VALOR trial. The companies are preparing regulatory submissions. Guggenheim reiterated a Buy rating with a $36.00 price target ahead of Pfizer Q1 2026 earnings report on May 5. China has also approved Pfizer GLP-1 treatment Xianweiying for weight management. Analyst sentiment remains mixed, with a $29.13 average price target indicating 6.5% upside potential.
Apr 14BofA lowers PT to $26; Morgan Stanley raises to $28; Lyme vaccine disappointsMixed▶
BofA cut PT to $26 Neutral. Morgan Stanley raised to $28. Lyme vaccine failed primary endpoint. Guggenheim reiterates Buy $36 PT. Dividend yield 6.4%.
Apr 13COVID vaccine trial halt; Q1 earnings on May 5Mixed▶
Pfizer and BioNTech halted a U.S. trial of their updated COVID-19 vaccine due to low enrollment ahead of May FDA advisory meeting. BofA lowered price target to $26. Q1 2026 EPS expected at $0.77 (down 16.3% YoY). Trump administration preparing tariffs on branded drugs. Positive Phase 2 results on atopic dermatitis drug tilrekimig.
Apr 10Pfizer annual meeting April 23; stock near 52-week low; Trump tariff concerns emerge.Neutral▶
Pfizer closed at $27.22, down 0.91% on April 9, with consensus Hold rating. Annual shareholder meeting scheduled for April 23. Trump administration preparing new pharmaceutical tariffs. Poland/Romania ordered to purchase $2.2B of Pfizer COVID vaccines. Stock faces headwinds from higher gross-to-net adjustments on premium drugs.
Apr 9Pfizer Agrees to Drug Price Reductions; Lyme Disease Vaccine ProgressMixed▶
Pfizer agreed to reduce prescription drug prices following Trump administration announcement, with some drugs seeing 50-100% price cuts. Company announced Lyme disease vaccine regulatory path forward with partner Valneva. RSV vaccine expanding in England to cover 3 million additional older adults. Pfizer closing South San Francisco research site and shifting roles to remote work.
Apr 8Pfizer closing South San Francisco R&D site; COVID revenue headwinds continue.Neutral▶
PFE at $26.88 (-3.41%). Closing South San Francisco R&D site, exiting ViiV for $1.875B, addressing cost pressures. 2026 guidance: $59.5-62.5B revenue, $2.80-3.00 adjusted EPS. COVID products expected $1.5B lower revenue. 14 analysts rate Buy. Average target $28.57.
Apr 7Pfizer navigates patent cliff headwinds with Lyme disease vaccine success and South San Francisco site closure for cost reduction.Neutral▶
Pfizer closed South San Francisco research site, shifting roles to remote in cost-cutting restructuring, while advancing late-stage vaccine pipeline. Company reported Lyme disease vaccine efficacy exceeding 70% in Phase 3 trial with partner Valneva, enabling regulatory filings. Stock up 1.67% at $28.55 with 4.7% weekly gain despite projected quarterly EPS of $0.77 (down 16.3% YoY). Major concern: $15-20B annual sales risk by 2030 from patent expirations on Ibrance, Eliquis, Xtandi, Vyndaqel with limited near-term replacements. Consensus Buy rating with $28.57 target implies minimal upside amid structural headwinds.
Apr 6Pfizer reaffirms 2026 revenue guidance $59.5-62.5B amid COVID product decline; Lyme vaccine 70%+ efficacy.Neutral▶
PFE reaffirmed 2026 guidance: revenue $59.5-62.5B, EPS $2.80-3.00 adjusted. Pivoting away from COVID products with 4% operational growth ex-COVID. Positive Phase 3 Lyme disease vaccine (70%+ efficacy) and prostate cancer therapy results. No share buybacks planned for 2026.
Apr 3Pfizer raises Q2 guidance on strong cancer drug sales and prostate cancer trial success, though full-year revenue guidance reflects COVID decline.Mixed▶
Pfizer provided full-year 2026 guidance of $59.5-62.5B revenue and $2.80-3.00 adjusted diluted EPS. COVID revenues expected $1.5B lower than 2025, plus $1.5B negative from products losing exclusivity. Talzenna combination met primary endpoint in TALAPRO-3 prostate cancer trial. Atirmociclib reduced breast cancer progression risk by 40% in Phase 2. Management plans to advance 15 programs. Guggenheim upgraded to Buy with $36 price target.
Apr 1Pfizer announces additional $1.2B cost-cutting program; annual shareholder meeting scheduled for April 23.Neutral▶
Pfizer revealed additional $1.2 billion cost-reduction efforts focused on selling, informational and administrative functions. Virtual annual shareholder meeting scheduled for April 23, 2026. Company received unsolicited mini-tender offer from Tutanota LLC for 1M shares at $32/share. Dr. Susan Hockfield retiring from Board effective April 2026. Earlier results showed Lyme disease vaccine positive Phase 3 trial outcomes and Ultra-Long-Acting Injectable GLP-1 RA showing robust weight loss.
Mar 31Pfizer advances pipeline with Phase 2 atirmociclib breast cancer results and Lyme vaccine plan with Valneva.Positive▶
Pfizer Phase 2 atirmociclib positive in metastatic breast cancer. Valneva partnership for Lyme vaccine regulatory approval. PADCEV plus Keytruda reduced recurrence 47%. GLP-1 RA showed monthly dosing weight loss. Stock up 11% YTD.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $964.50 | +3.20% | +0.8% | 22.2x | 0.50 | $834.9B |
| JNJJOHNSON | $227.78 | -0.90% | -4.6% | 18.1x | 0.33 | $553.3B |
| MRKMERCK | $112.32 | +2.88% | -9.7% | 11.2x | 0.28 | $269.7B |
| PFEPFIZER | $26.37 | -1.25% | -4.1% | 9.5x | 0.39 | $151.9B |
| BMYBRISTOL | $58.19 | -3.97% | +2.1% | 9.9x | 0.27 | $123.7B |
| ZTSZOETIS | $114.35 | -0.54% | -2.8% | 15.2x | 0.97 | $48.5B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price between 50d and 200d. Testing 50d support.